blonanserin has been researched along with aripiprazole in 4 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (aripiprazole) | Trials (aripiprazole) | Recent Studies (post-2010) (aripiprazole) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 2,989 | 509 | 1,788 |
| Protein | Taxonomy | blonanserin (IC50) | aripiprazole (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.78 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0158 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.945 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.38 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.42 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 1 |
| Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
| Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A | 1 |
| Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y | 1 |
2 trial(s) available for blonanserin and aripiprazole
| Article | Year |
|---|---|
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome | 2022 |
2 other study(ies) available for blonanserin and aripiprazole
| Article | Year |
|---|---|
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum | 2018 |